Aug 31, 2022
With an early stage budget of €25,000,000 each, Normax is currently developing mRNA vaccines for: SARS-C0V-2 Tuberculosis (TB) HIV Malaria VIDEO: mRNA Vaccines in Development by Normax...Aug 31, 2022
Vaxcomm is The Vaccine Freedom to Operate (FTO) Commons Our Focus: mRNA technology applied to infectious disease, treatments, cancers, global public health and pandemic preparedness. Vaxcomm is a Global Public Health Commons with Open Participation and Membership...Aug 31, 2022
mRNA vaccine technology is a transformative new sector of the biopharmaceutical industry which has revolutionised vaccine development through increased speed, safety and cost-effective development leading to the first approved vaccines for the COVID-19 pandemic. How...Aug 31, 2022
1. mRNA Vaccine R&D Normax conducts mRNA Vaccine R&D with a standardized mRNA vaccine technology in cooperation with leading scientist and researchers around the world. 2. mRNA Vaccine Manufacturing mRNA Vaccine Manufacturing with modular GMP regulatory...Aug 31, 2022
Normax estimates that the average cost for Normax Vax Factory to manufacture mRNA Vaccines at large scale for infectious diseases is about $2.00 per dose, or less. Normax plans to sell our mRNA Vaccines for infectious diseases on large scale advance purchase...